Q-omics provides the consensus-scored MIR410 profile across patient tissues and cancer cell-line models. MIR410 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR410 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR410 RNA expression shows 13,310 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, BRCA, and THYM as cancer lineages where MIR410 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR410 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR410 survival associations across molecular data types. MIR410 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR410 RNA expression–survival associations across cancer types. High MIR410 expression shows unfavorable associations in KICH, STAD, BLCA, SKCM and MESO, but favorable associations in LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR410 RNA expression.
This table summarizes MIR410 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR410. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR410 shows lower tumor expression in BRCA and UCEC. The BRCA box plot shows higher MIR410 RNA expression in normal versus tumor tissue (log2 FC = −0.148, t-test p < 0.001).
This table shows molecular features associated with MIR410 in patient tissues and cancer cell lines. In patient samples, MIR410 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
